Mer från bolag Publicerat: 2018-01-09 14:16:00

SensoDetect AB: SensoDetect -Signs Letter Of Agreement for study in Bolivia

SensoDetect and The Bolivian Distributor have signed a letter of agreement to conduct an initial study in a specialist hospital in central Bolivia. This study will start in February/march this year and will be  based on the new BERA 3.0.

The agreement is covering three steps that will evaluate and test the BERA 3.0 in the local population and set up the structure for further commercialisation.

-The first step involves a study being conducted on a secured group of diagnosed patients and a group of healthy controls.

- Then validations of the tests will be done by SensoDetect to ensure that all equipment and handling work on the specific population. This to verify and ensure that the local population corrolates to the data used for the test and that the response provides the intended support to the doctor.

-Step three means that the equipment will be optimized and the distributor trained for service and support. The system of direct diagnosis is set up so that SensoDetect and the Distributor can begin the launch of systems and get paid per use (PPU).

In this case, all steps from study to launch are expected to take 3 to 6 months.

The distributor has previously announced that they have a further six declarations of interest from other hospitals and clinics around Bolivia, which gives a good indication of an interest from Bolivia in general and a potential for relatively rapid expansion from the now specified hospital to a few new hospitals and clinics after the study has been conducted.

"It is very positive that we have now reached an agreement to do a study in a highly reputable hospital in Bolivia. The Distributor's commitment and experience is very positive and I would like to see an expansion further out of Bolivia to other parts of South America and it is, as I said, mutual. But first we want to establish that all tests are as good for this population as in the past and also that the BERA 3.0 gives the efficiency gain that we believe it will provide both in simplified operation but also in quick responses directly to the referring physician."says CEO Johan Olson, SensoDetect AB (Publ.)SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Our Mission
Improve the lives of people with mental illness
Our Vision
Making ABR profiling tests with SensoDetect technology an integral part of setting diagnosis for mental illness
Our Value Proposition:
SensoDetect provides a complete audiogram for the brainstem, helping health care professional to set psychiatric diagnoses objectively and
cost effectively. This unique offering improves patients' quality of life and reduces the economic impact on the health care system and societyJohan Olson

VD, SensoDetect Aktiebolag (publ)

Phone: +46 705 424600

e-mail: jo@sensodetect.com